Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.60 |
| ▸ | TYR | P14679 | 2/20 | 0.58 |
| ▸ | CTSL | P07711 | 2/20 | 0.58 |
| ▸ | CTSB | P07858 | 2/20 | 0.58 |
| ▸ | CTSS | P25774 | 2/20 | 0.58 |
| ▸ | CTSK | P43235 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.56 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5887266 | 1.00 | TACR1 (0.60) | TACR1TYRCTSLCTSBCTSS | |
| SCHEMBL5887348 | 0.92 | CTSL (0.57) | TACR1TYRCTSLCTSBCTSS | |
| SCHEMBL5887352 | 0.92 | CTSL (0.57) | TACR1TYRCTSLCTSBCTSS | |
| SCHEMBL5887270 | 0.92 | ALDH1A1 (0.65) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL5887268 | 0.92 | ALDH1A1 (0.65) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL23742613 | 0.92 | ITGB3 (0.63) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL7469563 | 0.92 | ITGB3 (0.63) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL15080871 | 0.92 | TACR1 (0.68) | TACR1TYRCTSLCTSBCTSS | |
| SCHEMBL3065366 | 0.89 | CTSL (0.64) | TACR1TYRCTSLCTSBCTSS | |
| SCHEMBL30343691 | 0.89 | CTSL (0.64) | TACR1TYRCTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7091373-B2 | Production method for biarylalanine | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-08-15 | — | — | US | disclosed |
| US-20040024229-A1 | Production method for biarylalanine | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-02-05 | — | — | US | disclosed |
| EP-1346971-A1 | Production method for biarylalanine | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024229-A1 | Production method for biarylalanine | BCAT2, BCAT1, PAH | TACR1 2442/4885TYR 18/4885CTSL 2254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.